---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017407"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:36:40.755832+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q3 net loss $4.56M ($0.38/share); cash $25.7M; CEO promoted; GT-02287 Phase 1 expected mid-2023

## Summary
- Net loss of $4.56M ($0.38 per share) vs $4.66M ($0.39) in Q3 2021.
- Cash, equivalents, and marketable securities $25.7M, providing runway into Q2 2024.
- R&D expenses $1.96M (down 21% YoY); G&A $2.79M (up 27% YoY).
- Matthias Alder promoted to CEO and appointed to board of directors.
- Lead Parkinson's candidate GT-02287 to commence Phase 1 trial in mid-2023.

## SEC filing metadata
- accession: 0001558370-22-017407
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837022017407/0001558370-22-017407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837022017407/ganx-20221110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017407
- JSON: https://secwatch.observer/filing/0001558370-22-017407.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017407.txt

## Key facts
- Earnings Releases
  Gain Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022, and business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000155837022017407/0001558370-22-017407-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.